Sintilimab Plus FOLFIRI as Salvage Therapy for Patients With Advanced Gastric Cancer

NCT06365008 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Unresectable/Metastatic Gastric Cancer

Interventions

DRUG: Sintilimab+irinotecan+leucovorin folinate+fluorouracil

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University